Hill-Rom (HRC) Upgraded to Buy at Zacks Investment Research
Hill-Rom (NYSE:HRC) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Monday. The brokerage presently has a $98.00 price target on the medical technology company’s stock. Zacks Investment Research‘s price objective would suggest a potential upside of 10.94% from the stock’s current price.
According to Zacks, “Hill-Rom has been witnessing an increase in revenues on strong international growth. The company is currently focused on gaining traction in the untapped international market on successful execution of its strategy, courtesy its efficient international team and organizational realignment. The company is focusing on product innovation through research and development. A slew of product launches in the fourth quarter is encouraging. Moreover, an improvement in adjusted and operating margin buoys optimism. Overall, Hill-Rom has outperformed the broader industry in the past six months. On the flip side, a decline in revenues at the Patient Support Systems segment is quite disappointing. Also, foreign exchange and a tough competitive landscape remain headwinds.”
Other equities research analysts also recently issued reports about the stock. ValuEngine downgraded shares of Hill-Rom from a “buy” rating to a “hold” rating in a research note on Saturday, November 4th. Stifel Nicolaus lifted their price objective on shares of Hill-Rom from $84.00 to $85.00 and gave the stock a “buy” rating in a research note on Monday, November 6th. Morgan Stanley downgraded shares of Hill-Rom from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, January 2nd. They noted that the move was a valuation call. KeyCorp reiterated a “buy” rating and set a $94.00 price objective on shares of Hill-Rom in a research note on Thursday, December 21st. Finally, Needham & Company LLC lowered their price objective on shares of Hill-Rom from $93.00 to $90.00 and set a “buy” rating for the company in a research note on Monday, November 6th. Six analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $91.75.
Shares of Hill-Rom (NYSE HRC) opened at $88.34 on Monday. The firm has a market cap of $5,810.00, a P/E ratio of 44.39, a price-to-earnings-growth ratio of 1.65 and a beta of 1.19. Hill-Rom has a one year low of $55.04 and a one year high of $88.91. The company has a quick ratio of 1.34, a current ratio of 1.77 and a debt-to-equity ratio of 1.55.
Hill-Rom (NYSE:HRC) last announced its earnings results on Friday, November 3rd. The medical technology company reported $1.32 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.27 by $0.05. The company had revenue of $738.30 million during the quarter, compared to the consensus estimate of $731.10 million. Hill-Rom had a net margin of 9.36% and a return on equity of 21.07%. Hill-Rom’s revenue was up 4.6% compared to the same quarter last year. During the same period last year, the firm earned $1.18 earnings per share. equities research analysts anticipate that Hill-Rom will post 4.32 EPS for the current year.
In related news, CEO John J. Greisch sold 125,241 shares of the business’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $82.59, for a total transaction of $10,343,654.19. Following the completion of the transaction, the chief executive officer now directly owns 280,851 shares in the company, valued at $23,195,484.09. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO John J. Greisch sold 100,000 shares of the business’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $82.82, for a total transaction of $8,282,000.00. Following the transaction, the chief executive officer now owns 230,851 shares of the company’s stock, valued at $19,119,079.82. The disclosure for this sale can be found here. Insiders have sold 226,241 shares of company stock valued at $18,708,644 over the last quarter. Insiders own 2.20% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. State Street Corp lifted its position in Hill-Rom by 2.7% during the second quarter. State Street Corp now owns 1,681,107 shares of the medical technology company’s stock valued at $133,831,000 after purchasing an additional 43,645 shares during the period. Principal Financial Group Inc. lifted its position in Hill-Rom by 8.5% during the third quarter. Principal Financial Group Inc. now owns 283,290 shares of the medical technology company’s stock valued at $20,963,000 after purchasing an additional 22,188 shares during the period. Amalgamated Bank lifted its position in Hill-Rom by 25.7% during the second quarter. Amalgamated Bank now owns 13,108 shares of the medical technology company’s stock valued at $1,044,000 after purchasing an additional 2,678 shares during the period. Fred Alger Management Inc. lifted its position in Hill-Rom by 163.3% during the second quarter. Fred Alger Management Inc. now owns 9,217 shares of the medical technology company’s stock valued at $734,000 after purchasing an additional 5,717 shares during the period. Finally, Magnetar Financial LLC lifted its position in Hill-Rom by 24.4% during the third quarter. Magnetar Financial LLC now owns 17,458 shares of the medical technology company’s stock valued at $1,292,000 after purchasing an additional 3,421 shares during the period. Institutional investors own 82.33% of the company’s stock.
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.